Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WIN-R: Weight-Based vs Fixed-Dose Ribavirin with PEG-Interferon Alfa-2b in HCV
NCT00299936Phase 3Completed
- Sponsor
- Weill Cornell Medicine
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of ribavirin in hepatitis C (HCV), sponsored by Weill Cornell Medicine. Status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00299936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299936.